Home Patent Forecast® Sectors Log In   Sign Up   Support   Contact  
Why Patent Forecast® What's Included Patent Forecast® Sectors Free Trial Pricing News Feed Subscribe Menu

Patent 10980756
First Wave Bio, Inc.

Methods Of Treatment

This disclosure features compounds and compositions that are useful in methods of treating coronavirus infections (e.g., useful in methods of treating COVID-19) in a subject in need thereof. The methods include administering to the subject niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide). In some embodiments, the niclosamide compounds have one or more properties that include, but are not limited to: a particular purity (e.g., a chemical purity of greater than about 99.0%) or a particular particle size (e.g., a particular particle size distribution and/or a particular particle size range and/or a specific surface area range). In an aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for respiratory administration (e.g., via inhalation and/or intranasally). In another aspect, the niclosamide compounds described herein (e.g., niclosamide) can form part of compositions, dosage forms (e.g., unit dosage forms), and the like, which are suitable for administration to the GI tract (e.g., orally or rectally such as via enema)).

Much More than Average Length Specification


1 Independent Claims

  • Claim 1. A method for treating a digestive symptom in a subject diagnosed as having a COVID-19 viral infection and in need of such treatment, the method comprising orallyadministering an effective amount of niclosamide: ##STR00010## or a pharmaceutically acceptable salt thereof, to the subjectwherein the effective amount of niclosamide, or a pharmaceutically acceptable salt thereof, decreases an amount ofCOVID-19-viral RNA load in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject by about 45% to about 99% relative to a baseline amount of COVID-19-viral RNA load, wherein the baseline amount of COVID-19 viral RNA loadis an amount of COVID-19-related viral RNA that is present in a fecal sample, an anal swab sample, or a rectal swab sample obtained from the subject prior to administration of the niclosamide, or a pharmaceutically acceptable salt thereof.
  • Claim 22. A method for treating a subject having a COVID-19 viral infection and is in need of such treatment, the method comprising orally administering an effective amount of niclosamide: ##STR00011## or a pharmaceutically acceptable salt thereof,to the subject so as to treat the COVID-19 viral infectionwherein the effective amount of niclosamide, or a pharmaceutically acceptable salt thereof, decreases an amount of COVID-19 viral RNA load in a fecal sample, an anal swab sample, or a rectalswab sample obtained from the subject by about 45% to about 99% relative to a baseline amount of COVID-19 viral RNA load, wherein the baseline amount of COVID-19 viral RNA load is an amount of COVID-19 viral RNA that is present in a fecal sample, an analswab sample, or a rectal swab sample obtained from the subject prior to administration of the niclosamide, or a pharmaceutically acceptable salt thereof.